RxDoctor Payments Data

Cameron Smith

Family · Plymouth, NCNPI 1821525692

Payments from drug & device makers

$306in general payments, 2019–2025

Across 17 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$90
  • AstraZeneca$39
  • Dexcom, Inc.$24
  • Xeris Pharmaceuticals, Inc.$24
  • Purdue Pharma L.p.$22
  • Biomerieux Inc$20
  • plus $88 from 6 others

What the payments were for

  • Food & beverage$306100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$306 in reported general payments places this provider in the 45th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$38,055
Medicare patients
83
Services billed
436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin78$57,528
EliquisApixaban70$52,287
OzempicSemaglutide32$36,524
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$28,415
FarxigaDapagliflozin Propanediol24$25,199
XareltoRivaroxaban29$21,992
JanuviaSitagliptin Phosphate19$18,612
MounjaroTirzepatide12$18,255
LinzessLinaclotide23$12,514
EntrestoSacubitril/Valsartan15$9,246
SymbicortBudesonide/Formoterol Fumarate21$6,964
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$6,843
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,032
Tresiba Flextouch U-100Insulin Degludec11$4,351
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$2,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$36,52432 claims
GSKTrelegy Ellipta, Anoro Ellipta$90$33,44849 claims
AstraZenecaFarxiga, Symbicort$39$32,16445 claims
Johnson & JohnsonXarelto$13$21,99229 claims
MerckJanuvia$14$18,61219 claims
Lilly USA, LLCMounjaro$15$18,25512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 4,522 family providers in North Carolina.

Other family in Plymouth

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →